Orchid Pharma Ltd. Share Price

Overview

Orchid Pharma Ltd. share price is currently ₹900.38, up by ₹26.51 (3.03%) from its previous closing price of ₹873.87. The share price has declined -2.32% over the past month and gained 8.25% over the past year. The stock's 52-week low and high are ₹474.67 and ₹1,135.65, respectively. Orchid Pharma Ltd. has a market capitalisation of ₹ 5,278.88 Cr. The share price was last updated on 16 Nov 2026, 03:29 PM IST.

Orchid Pharma Ltd.
Orchid Pharma Ltd.
ORCHPHARMA
 ₹0.00
 ₹26.51
3.03%
Healthcare
 ₹0.00(%)1D

Updated: 16 Nov 2026, 03:29:55 pm IST

Market Data

Open Price

 ₹876.84

Prev. Close

 ₹873.87
 ₹876.84

Day Low

 ₹974.44

Day High

 ₹474.67

52 Week Low

 ₹1,135.65

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

119.89

Sector PE

45.97

PB Ratio

0.91

Sector PB

6.03

EPS

7.51

Dividend Yield

0.00

Today's Volume

466.147 K

5 Day Avg. Volume

134.581 K

PEG Ratio

-1.29

Market Cap.

₹ 5,278.88 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Corporate Actions will be available shortly.

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
Quant Small Cap Fund - Growth34.66 Lac
34.66 Lac
no change
UTI Value Fund - Regular Plan - Growth11.89 Lac
11.81 Lac
(0.69%)
Invesco India Contra Fund - Regular Plan - Growth9.91 Lac
9.91 Lac
no change
Kotak Multi Asset Allocation Fund - Regular Plan - Growth9.43 Lac
9.43 Lac
no change
UTI Small Cap Fund - Regular Plan - Growth5.10 Lac
5.10 Lac
no change

About Orchid Pharma Ltd. 👋

Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of formulations and active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, and Veterinary Products. Its formulations include Cefixime Capsules, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Bio-Pharma Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc. and Diakron Pharmaceuticals, Inc.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Vibhu Jain

Vibhu Jain

4 Nov • 7:31 AM · SEBI-Registered Analyst

Orchid Pharma analysis on different parameters

ORCHPHARMA Quality :- The company’s quality metrics are assessed as average, reflecting a stable but unremarkable operational profile. Over the last five years, operating profit has grown at an annual rate of approximately 15.60%, indicating moderate expansion in core earnings. However, this growth has not translated into strong profitability ratios, with the average return on equity (ROE) hovering near 4.82%, a figure that suggests limited efficiency in generating shareholder returns. Valuation :- Valuation metrics suggest that the stock is trading at a premium relative to its peers and historical averages. The enterprise value to capital employed ratio is approximately 3.4, which is considered very expensive in the context of the company’s subdued profitability and flat financial results. This premium valuation may reflect investor expectations of future growth or sector-specific optimism, but it also introduces a degree of risk should earnings fail to meet these expectations. Financial :- Financial trends reveal some concerns, particularly regarding the company’s leverage and capital structure. The debt to EBITDA ratio is notably high at 14.73 times, signalling a significant debt burden relative to earnings before interest, tax, depreciation, and amortisation. This elevated leverage raises questions about the company’s ability to service its debt obligations comfortably over the long term. Technical :- technical standpoint, the stock exhibits mildly bullish characteristics. Recent price movements include a one-day gain of 1.37% and a one-week increase of 2.70%, although the one-month and three-month returns have been negative, at -13.51% and -13.14% respectively. Over six months, the stock has rebounded with a 36.45% gain, underscoring some volatility but also resilience in the medium term.

See More
Vibhu Jain

Vibhu Jain

24 Oct • 7:19 AM · SEBI-Registered Analyst

Orchid Pharma analysis on different parameters

ORCHPHARMA Quality :- The company’s quality grade remains average, indicating a moderate level of operational efficiency and business fundamentals. Over the past five years, operating profit has expanded at an annual rate of approximately 15.6%, signalling some growth momentum. However, this growth is tempered by a relatively low return on equity, averaging 4.82%, which suggests limited profitability generated per unit of shareholders’ funds. Valuation :- Valuation remains a key factor in the recent evaluation revision. Orchid Pharma Ltd is considered very expensive relative to its capital employed, with an enterprise value to capital employed ratio of 3.5. This premium valuation contrasts with the company’s subdued profitability metrics, including a return on capital employed (ROCE) of -0.9%, which is notably low. Financial :- Financial trends for Orchid Pharma Ltd show a relatively flat trajectory in recent periods. The company reported a PAT of ₹23.78 crores for the nine months ended June 2026, reflecting a contraction of 36.38% compared to prior periods. The half-year ROCE stood at a low 1.27%, while the debt-to-equity ratio increased to 0.28 times, marking the highest level in recent history. Technical :-a technical perspective, the stock exhibits a mildly bullish stance. However, recent price movements have been volatile, with the stock declining by 2.95% on the latest trading day and showing a one-month drop of nearly 23%. Over six months, the stock has delivered a positive return of 50.27%, while the year-to-date gain stands at 11.95%, and the one-year return is approximately 17.08%.

See More
Clovek Advisory

Clovek Advisory

20 Oct • 7:51 PM · SEBI-Registered Analyst

Board approve enabling resolution explore raising upto 600Cr

ORCHPHARMA 's Board met on October 20, 2026 and approved an enabling resolution to explore options for raising funds. Indicative size: up to Rs. 600 Crores (Rupees Six Hundred Crore Only). Possible routes: equity shares, other eligible securities or instruments, fully or partly convertible debentures, QIP, private placement, public issue of equity shares and/or debt securities, preferential issue or any ***** to statutory and regulatory approvals, and member approval where ***** filing states the required information is not available as on date. Size vs market cap: Rs 600 crore is ~11.2% of the stated market cap (Rs 5,351 cr), so a material capital raise but not a takeover-size event. Dilution risk: a primary-equity route at market prices could dilute existing shareholders by roughly the same order (single-digit to low-double-digit %), depending on issuance method and pricing. Promoter control: promoters hold 74.45% — preferential/private placement to promoters or allotment with promoter participation would preserve control but could further entrench promoter share; an open QIP or public issue would dilute promoter/public proportions depending on participation. Balance sheet/leverage trade-off: current debt-to-equity is low (0.2x). Raising the full amount as debt would materially increase leverage and financial risk, while equity issuance would conserve leverage but dilute earnings per share.

See More
CA Sumit Mangla

CA Sumit Mangla

20 Oct • 4:12 PM · SEBI-Registered Analyst

Orchid Pharma board approves fundraising up to ₹600 Cr

ORCHPHARMA Orchid Pharma Limited (ORCHPHARMA) has received board approval to explore fundraising of up to ₹600 crore. The proposed securities include equity shares and eligible financial instruments such as fully or partly convertible debentures. Potential routes under consideration include Qualified Institutional Placement (QIP), private placement, public issue, preferential issue, or a combination thereof. The fundraising remains subject to regulatory and shareholder approvals where applicable. Issue structure, number of securities, and the final amount are yet to be decided. The key trigger is the enabling resolution for a potential capital raise of up to ₹600 crore, which provides flexibility to fund expansion plans including the company’s ongoing projects in antibiotic intermediates. This is positive for growth visibility but remains non-binding at this stage. Peers such as Aurobindo Pharma, Laurus Labs, and Granules India may face comparison on capital-raising and API capacity expansion. Near-term prices could react positively on the growth funding narrative, though dilution concerns may limit upside until pricing details emerge. Risks include final terms being less favourable, delay in approvals, or higher-than-expected equity dilution. Competitors listed: Aurobindo Pharma, Laurus Labs, Granules India.

See More
Shrikant Pandey

Shrikant Pandey

20 Oct • 1:21 PM · SEBI-Registered Analyst

ORCHPHARMA: BOARD APPROVES FUND RAISE OF UP TO ₹600 CR

ORCHPHARMA: BOARD APPROVES FUND RAISE OF UP TO ₹600 CR ORCHPHARMA • Board approved an enabling resolution to explore raising up to ₹600 Cr in the best interest of the company • Fund raise may be through equity shares or other eligible securities/instruments, including fully or partly convertible debentures • Proposed routes include QIP, private placement, public issue of equity and/or debt, preferential issue, or any combination thereof • Fund raise remains subject to statutory and regulatory approvals, including shareholder approval wherever applicable • Type of issuance, number of securities and final amount have not been decided as of now Impact: Positive — The enabling approval provides Orchid Pharma with flexibility to raise up to ₹600 Cr for future growth and funding requirements. However, the actual impact will depend on the final structure, pricing and potential dilution.

See More
Clovek Advisory

Clovek Advisory

24 Aug • 3:20 PM · SEBI-Registered Analyst

Orchid Pharma posted decent number in Q1 of the FY 27

ORCHPHARMA announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: For Q1FY27, revenue from operations stood at Rs 30,417.13 lakh, registering a growth of 15.57% YoY compared to Rs 26,318.58 lakh in Q1FY26. On a QoQ basis, revenue decreased by 17.42% from Rs 36,832.71 lakh in Q4FY26. Total Income: The company reported a total income of Rs 30,599.97 lakh in Q1FY27, up 11.37% YoY from Rs 27,475.56 lakh in Q1FY26, but down 18.64% QoQ from Rs 37,610.08 lakh in Q4FY26. Net Profit: Net Profit for Q1FY27 was reported at Rs 322.44 lakh, showing a significant turnaround YoY from a Net Loss of Rs 569.22 lakh in Q1FY26. However, it saw an 87.52% decrease QoQ compared to Rs 2,583.94 lakh in Q4FY26. Total Comprehensive Income: Total comprehensive income for Q1FY27 was Rs 323.08 lakh, compared to a loss of Rs 584.70 lakh in Q1FY26 and a profit of Rs 2,714.21 lakh in Q4FY26.

See More

News & Events

Frequently Asked Questions

What is the share price of Orchid Pharma Ltd.?

What is the market cap of Orchid Pharma Ltd.?

Should I buy Orchid Pharma Ltd. stock now?

What is the 52 week high and low of Orchid Pharma Ltd.?

Is the Orchid Pharma Ltd. stock good to buy?

Is Orchid Pharma Ltd. a good buy for the long term?

Is Orchid Pharma Ltd. overvalued or undervalued?

What is the PE and PB ratio of Orchid Pharma Ltd.?

Start Now